Moreover, adjuvant osimertinib showed longer disease-free survival (DFS) compared with placebo in patients with stage Ib-IIIa EGFR-mutant NSCLC (Wu et al., 2020). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.